Development of a Desmocollin-3 Active Mouse Model Recapitulating Human Atypical Pemphigus
August 2019
New to Prednisolone? There is a guide in the encyclopedia. Read the guide → Studysummary In this study, researchers developed a pemphigus mouse model expressing anti-Desmocollin 3 antibodies and found it mimicked atypical pemphigus with distinct pathological features compared to the standard Desmoglein 3 model.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study developed a mouse model to investigate the role of anti-Desmocollin 3 (DSC3) antibodies in pemphigus, an autoimmune blistering disease. The model involved transferring DSC3 and/or Desmoglein 3 (DSG3) lymphocytes to immunodeficient mice. Results indicated that anti-DSC3 antibodies alone could induce a pemphigus-like phenotype with erythema and patchy hair loss, differing from the DSG3 model. The presence of both antibodies led to a more severe condition with frequent erosions and exacerbated symptoms. Histological analysis showed classical acantholysis, epidermal spongiosis, and dermal inflammation. The DSC3/DSG3 model also had a slower response to prednisolone treatment, suggesting that antigens other than desmogleins might contribute to different pemphigus phenotypes.
